Page last updated: 2024-11-11

cycloheterophyllin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cycloheterophyllin: RN refers to ((+)-)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5316250
CHEMBL ID461820
CHEBI ID175844
MeSH IDM0278770

Synonyms (22)

Synonym
36545-53-6
CHEBI:175844
6,7,15-trihydroxy-19,19-dimethyl-22-(3-methylbut-2-enyl)-11-(2-methylprop-1-enyl)-2,10,20-trioxapentacyclo[12.8.0.03,12.04,9.016,21]docosa-1(14),3(12),4,6,8,15,17,21-octaen-13-one
MLS000697580 ,
cycloheterophyllin
smr000470928
cycloheterphyllin
CHEMBL461820
LMPK12110921
NCGC00247520-01
cid_5316250
bdbm53429
6h,7h,11h-bis(1)benzopyrano(4,3-b'':6',7'-e)pyran-7-one, 2,3,8-trihydroxy-11,11-dimethyl-13-(3-methyl-2-butenyl)-6-(2-methyl-1-propenyl)-, (+)-
HMS2269P06
2,3,8-trihydroxy-11,11-dimethyl-13-(3-methyl-2-butenyl)-6-(2-methyl-1-propenyl)-6h,7h,11h-bis[1]benzopyrano[4,3-b:6',7'-e]pyran-7-one, 9ci
AKOS032961800
FS-9310
6,7,15-trihydroxy-19,19-dimethyl-22-(3-methylbut-2-enyl)-11-(2-methylprop-1-enyl)-2,10,20-trioxapentacyclo[12.8.0.0^{3,12.0^{4,9.0^{16,21]docosa-1(14),3(12),4,6,8,15,17,21-octaen-13-one
DTXSID20957840
2,3,8-trihydroxy-11,11-dimethyl-13-(3-methylbut-2-en-1-yl)-6-(2-methylprop-1-en-1-yl)-6h,7h,11h-[1]benzopyrano[3',4':5,6]pyrano[3,2-g][1]benzopyran-7-one
HY-N3667
CS-0024025
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
extended flavonoidAny flavonoid with one or more rings fused on to the phenyl substituted benzopyran framework.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.48130.631035.7641100.0000AID504339
acid sphingomyelinaseHomo sapiens (human)Potency398.107014.125424.061339.8107AID504937
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978; AID686979
PINK1Homo sapiens (human)Potency50.11872.818418.895944.6684AID624263
67.9K proteinVaccinia virusPotency10.61010.00018.4406100.0000AID720579; AID720580
ParkinHomo sapiens (human)Potency50.11870.819914.830644.6684AID624263
chromobox protein homolog 1Homo sapiens (human)Potency14.12540.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency22.38723.548119.542744.6684AID743266
gemininHomo sapiens (human)Potency1.52080.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Ubiquitin carboxyl-terminal hydrolase isozyme L3Mus musculus (house mouse)IC50 (µMol)12.00000.94000.94000.9400AID1799485
Ubiquitin carboxyl-terminal hydrolase isozyme L1Mus musculus (house mouse)IC50 (µMol)12.00000.94000.94000.9400AID1799485
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein 90Candida albicansEC50 (µMol)12.99100.12006.485533.8530AID2423
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)75.94150.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID355021Inhibition of ram seminal vesicle cyclooxygenase pretreated 2 mins before arachidonate substrate addition1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID355018Antiplatelet activity against human platelets in platelet rich plasma assessed as adrenaline-induced platelet aggregation at 100 uM pretreated 3 mins before adrenaline challenge by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID354988Antiplatelet activity against rabbit platelets assessed as platelet-activating facto-induced platelet aggregation at 300 uM by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID355013Antiplatelet activity against rabbit platelets assessed as arachidonic acid-induced platelet aggregation by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID354987Antiplatelet activity against rabbit platelets assessed as collagen-induced platelet aggregation at 300 uM by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID355017Antiplatelet activity against human platelets in platelet rich plasma assessed as adrenaline-induced platelet aggregation at 150 uM pretreated 3 mins before adrenaline challenge by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID354986Antiplatelet activity against rabbit platelets assessed as arachidonic acid-induced platelet aggregation at 300 uM by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID354989Antiplatelet activity against rabbit platelets assessed as thrombin-induced platelet aggregation at 300 uM by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID355016Antiplatelet activity against human platelets in platelet rich plasma assessed as adrenaline-induced platelet aggregation at 300 uM pretreated 3 mins before adrenaline challenge by turbidimetric method1996Journal of natural products, Sep, Volume: 59, Issue:9
Novel antiplatelet constituents from formosan moraceous plants.
AID1799485Inhibition Activity Assay from Article 10.1016/j.chembiol.2003.08.010: \\Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.\\2003Chemistry & biology, Sep, Volume: 10, Issue:9
Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]